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Abstract
Background: In patients with septic shock mortality is high, and survivors experience long-term 
physical, mental and social impairments. The ongoing Conservative vs Liberal Approach to fluid 
therapy of Septic Shock in Intensive Care (CLASSIC) trial assesses the benefits and harms of a 
restrictive versus (vs) standard-care intravenous (IV) fluid therapy. The hypothesis is that IV fluid 
restriction improves patient-important long-term outcomes.
Aim: To assess the predefined patient-important long-term outcomes in patients randomised 
into the CLASSIC trial. 
Methods: In this pre-planned follow-up study of the CLASSIC trial, we will assess all-cause 
mortality, Health-Related Quality of Life (HRQoL) and cognitive function one year after 
randomisation in the two intervention groups. The 1-year mortality will be collected from 
electronic patient records or central national registries in most participating countries. We will 
contact survivors and assess EuroQol 5-Dimension, -5-Level (EQ-5D-5L) and EuroQol-Visual 
Analogue Scale and Montreal Cognitive Assessment 5-minute protocol score. We will analyse 
mortality by logistic regression and use general linear models to assess HRQoL and cognitive 
function.
Discussion: With this pre-planned follow-up study of the CLASSIC trial, we will provide patient-
important data on long-term survival, HRQoL and cognitive function of restrictive vs standard-
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Introduction
Sepsis is a syndrome with a dysregulated host response to an infection; in the most severe cases 
septic shock, multiple organ failure and death are frequent.1 Sepsis contributes to every third 
hospital death.2 Patients surviving septic shock often have long-term physical, psychological and 
cognitive disabilities with health-related and social implications.3–7 Any improvement in the 
treatment of septic shock is estimated to have a significant impact on public health and health 
economy.3  
Intravenous (IV) fluid therapy is a recommend key intervention in septic shock, however, the 
evidence on how to manage fluids in these ICU setting is of low quality.6,8,9 Therefore, the 
ongoing multi-centre, randomised clinical trial (RCT) “The Conservative vs Liberal Approach to 
fluid therapy of Septic Shock in Intensive Care” (CLASSIC) assesses the benefits and harms of IV 
fluid restriction vs standard care in adult intensive care unit (ICU) patients with septic shock.10
Health-related quality of life
Health-related quality of life (HRQoL) is the most frequently used patient-reported outcome 
measure (PROM) for patients surviving critical illness in ICU.11–13 HRQoL instruments offer a 
comprehensive multidimensional approach assessing physical, mental, and social domains and 
an overall perceived health state.14,15 The HRQoL measure is, therefore, an important outcome 
measure in addition to survival.15
Most often HRQoL is assessed in ICU survivors using generic, non-disease-specific instruments, 
most frequently the Short Form 36-item questionnaire or the EuroQol 5 dimension scale (EQ-
5D).13 The EQ-5D is a short HRQoL questionnaire including domains on mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression.16 The EQ-5D is considered validated to be 
used for follow-up in ICU trials to assess self-perceived HRQoL17–20 and is recommended as a core 
outcome measure in this setting.21 The EQ-5D comes in two versions: a 3-level and a 5-level 
version. The EQ-5D in five levels (EQ-5D-5L) is to be answered together with an EQ-Visual 
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Cognitive function
Long-term cognitive impairment after critical illness is defined as the neuro-psychological 
changes that tend to persist and cause deficits of a magnitude that impair daily function.22 The 
incidence of cognitive impairment after sepsis has been reported to range from 4% to 62%.23,24 
Both physical and cognitive impairment after intensive care are likely modifiable outcomes25 as 
well as being outcomes reported as important to patients who survived acute respiratory 
failure.26 
The Montreal Outcome Assessment (MoCA) is a validated tool to assess cognitive function.27 The 
full MoCA score is based on face-to-face interviews, but these are challenging to perform in large 
trials. The Mini MoCA refers to the MoCA 5-minute protocol,28 previously validated in stroke-
patients, consisting of five cognitive domains from the full MoCA for assessing mild cognitive 
impairment.28 The five domains are attention, verbal learning and memory, executive 
function/language and orientation covered by four subtests.28 
Fluid trials for patients with septic shock measuring 1-year follow-up
A systematic review and meta-analysis, assessing lower vs higher fluid volumes in patients with 
septic shock, including nine trials, is in review.29 None of these nine trials assessed long-term 
patient-important outcomes like HRQoL or cognitive function.
In the Fluid and Catheters Treatment Trial (FACTT) patients with acute lunge injury were 
randomised to conservative vs standard fluid therapy after the initial management.30 In an 
adjunct study to the FACTT trial, a potential association between the conservative fluid-
management strategy and long-term cognitive impairment was found in survivors25 when 
assessed after 12 months by a validated neurocognitive telephone test at 12 months.25,31 The 
authors could not explain the result by reduced cerebral perfusion (e.g. cardiac index, systolic 
blood pressure) and encouraged further research to validate this result.25
At least two ongoing restricted vs standard IV fluid trials in patients with sepsis/septic shock are 
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follows patients until day 90 with in-hospital mortality as primary outcome,32 and the CLASSIC 
trial follows patients until one year, assessing mortality, HRQoL and cognitive function.10 The 
CLASSIC trial seems to be the only trial measuring long-term patient-important-outcomes.10
Aim
To assess the predefined patient-important, long-term outcomes in patients randomised in the 
CLASSIC trial. 
Hypothesis
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Method
The CLASSIC trial
CLASSIC is an ongoing investigator-initiated, international, parallel-grouped, randomised 1:1 by a 
computer-generated allocation sequence list, stratified, analyst-blinded trial (NCT03668236). In 
the CLASSIC trial we assess benefits and harms of restricted vs standard-care IV fluid therapy in 
adult ICU patients with septic shock, stratified for haematological or metastatic cancer (yes/no) 
and trial site.10 The protocol and statistical analysis plan for the 90-day follow-up have been 
published.10 The planned sample size is 1554 patients. The first patient was enrolled November 
27th, 2018, and the last patient is expected November 27th, 2020, with 1-year follow-up of the 
last patient by November 27th, 2021.
The primary outcome is mortality at day 90 and secondary outcomes are serious adverse events, 
serious adverse reactions, days alive at day 90 without life support, days alive and out of hospital 
at day 90, and mortality, HRQoL and cognitive function at one year.
Study design
This is a pre-planned long-term follow-up study assessing secondary outcomes of the CLASSIC 
trial. The staff assessing HRQoL and cognitive function and the statistician will be blinded to the 
trial allocation. 
Study population
All patients randomised in the CLASSIC trial for whom there is obtained consent to carry out 1-
year follow-up.
Inclusion criteria
All the following criteria must be met:
 Aged 18 years or above
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 Septic shock defined according to the Sepsis-3 criteria:1
o Suspected or confirmed site of infection or positive blood culture AND
o Ongoing infusion of vasopressor/inotrope agent to maintain a mean arterial blood 
pressure of 65 mmHg or above AND
o Lactate of 2 mmol/L or above in any plasma sample performed within the last 3 
hours
 Have received at least 1 L of IV fluid (crystalloids, colloids or blood products) in the last 24 
hours prior to screening.
Exclusion criteria
Patients who meet any of the following criteria will be excluded:
 Septic shock for more than 12 hours at the time of screening
 Life-threatening bleeding 
 Acute burn injury of more than 10% of the body surface area 
 Known pregnancy 
 Consent not obtainable 
Outcomes at 1-year follow-up
 All-cause mortality 
 HRQoL measured by the EQ-5D-5L and EQ-VAS
 Cognitive function as assessed by the Mini MoCA 
Ethical approval
The CLASSIC trial is registered at the European Clinical Trials Database (2018-000404-42) and 
www.clinicaltrials.gov (NCT03668236), is approved by the Danish Medicines Agency 
(2018020596), the Ethics Committee of the Capital Region (H-18006255), and the Danish Data 
Protection Agency (VD-2018-392) and by the relevant authorities for all participating sites. 
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Protection of data
At enrolment each patient receives a unique trial identification number in the electronic case 
report form (eCRF). All data will be obtained from patient files and national registers and 
recorded in a secured web-based eCRF. Data are managed electronically in the eCRF by trained 
trial personnel and will be handled according to the National Data Protection Agency and 
protected by the Danish national laws.33,34 
Workflow
We will introduce a Standard Operating Procedure (SOP) to be followed for all patients to 
motivate a high response rate and uniform data collection.35,36 Patients withdrawn from the 
intervention who have accepted further data registration will be contacted for the 1-year follow-
up.
Obtaining survival status
We will obtain 1-year survival status for all patients. One-year mortality post randomisation will 
be obtained by registry for all Danish patients. At the sites in other countries it will be obtained 
as feasible. If the patient has deceased, date of death will be registered.
Telephone interviews
Each site will conduct telephone interviews with all survivors at 1-year post randomisation 
(allowing four additional weeks to increase the likelihood of response). Each site must secure 
that the personnel, who contacts the patients is blinded to the trial allocation.
Obtaining Mini MoCA
Every site will receive a version of the Mini MoCA in their language and the SOP on how to obtain 
the Mini MoCA. To increase consistency, all assessors will obtain training and certification 
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interview with the Mini MoCA to ensure this is completed, in case the patient gets tired. Also, it 
is important that the patient is placed in a quiet room with no other people (to avoid noise and 
help) and not facing a calendar due to a question concerning orientation in the cognitive function 
score.37 The Mini MoCA28 can only be answered by the patient directly by phone and not by 
proxy. If the Mini MoCA has not been released for use at the time of the first assessment (one 
year after randomisation of the first patient), we will adapt the Mini MoCA from the MoCA full v. 
7.1 with acceptance from the author.
Obtaining EQ-5D-5L
Every participating site will receive a version of the questionnaire in their language and the SOP 
on how to obtain the EQ-5D-5L. The EQ-5D-5L and the EQ-VAS scores can be obtained by phone, 
as we recommend, or by mail, if the patient prefers this. If the patient is not cognitively able to 
participate, we will ask a relevant proxy to answer.15 There is a proxy version of the EQ-5D-5L in 
all languages needed for the trial. In this version the proxy is asked to rate the patients’ HRQoL in 
their (the proxies) opinion.
Statistical analyses
We will conduct all analyses in the intention-to-treat (ITT) population defined as all randomised 
patients for whom there is consent for the use of data. If the distribution of HRQoL and Mini 
MoCA deviates substantially from the normal distribution the primary analysis will be adjusted 
for the stratification variable of sites using Van Elteren test for differences of medians between 
groups. If the distribution of HRQoL and Mini MoCA comes close to a normal distribution or if the 
distribution of the Log transformed data comes close to a normal distribution, we perform 
multiple linear regression adjusted for both the stratification variable of sites and haematological 
malignancy.  
In the two intervention groups we will assess any differences in:
 One-year mortality using two-tailed logistic regression adjusted for the stratification 
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model (GLM) with appropriate link functions and binomial error-distribution) to 
consistently report the latter. We will present a Kaplan-Meier curve for the crude data. 
 EQ-5D-5L, EQ-VAS and Mini MoCA scores using a generalised linear model or 
nonparametric test stratified for site (the rating and calculation is described in a 
Supplemental File S1). We have considered the challenge of handling patients “truncated 
due to death” when analysing functional outcomes in trials.38 In consensus, we decided to 
assume that death is worse than a low HRQoL or low cognitive function score. Patients 
who are dead at 1-year follow-up will therefore be assigned the worst possible value (a 
value of zero). This will make these data non-normally distributed. We will, therefore, 
compare the groups using the method of Lange and Kryger Jensen; the probability of 
having a zero will be modelled using a logistic regression while the mean value among the 
non-zero values will be modelled using linear regression.39 A joint test for no treatment 
effect will be reported.  
 The scores of the single sub-domains of the EQ-5D-5L and the Mini MoCA will be 
presented in a supplement.
With 2 x 777 patients and a control event rate of 55% for the mortality at 1-year,40,41 we will have 
an 80% statistical power to detect a 15% relative risk reduction in the fluid restriction group vs 
the standard-care group with a type 1 error level of 1% . The estimates of the control event rates 
originate from data of previous septic shock trials.40,41 We expect HRQoL and cognitive function 
at 1-year to be highly skewed (non-normally distributed). As we lack knowledge on the details of 
the distribution, no realistic power analysis can be provided. We therefore refrain from this to 
avoid creating a false impression of precision. We will also conduct sensitivity analyses of EQ-5D-
5L and Mini MoCA in the survivors only.
Significance
We will provide 99% confidence intervals (CI) between means (if data are nearly normally 
distributed) or otherwise between medians (by bootstrapping). We will present the results as 
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appropriate link functions and binomial error-distribution, using 99% CIs for the secondary 
outcomes (P-value 0.01) due the multiplicity of these as stated in the CLASSIC protocol.10 
Patients with missing data
Patients who die before 1-year follow-up will not create missingness. There are the following 
reasons for having missing data: 
 Lost to follow-up (missing vital status and the EQ-5D-5L, EQ-VAS and the Mini MoCA data)
 Patients known to be alive who cannot be contacted or do not respond (missing EQ-5D-5L 
and Mini MoCA data).
We will obtain the reasons for missing data (Supplemental file S2); these will be described in the 
main manuscript and presented in supplementary material. If data in the completed 
questionnaires are missing exclusively for the outcome of EQ-5D-5L and the Mini MoCA in less 
than 5% or more than 40% of patients, or data are Missing Completely At Random (MCAR) with a 
negative Little’s test (P>0.05), we will not impute missing data.42 
If data are missing for outcomes in more than 5% and less than 40% of the patients, data will be 
imputed using multiple imputation (MI) assuming data missing at random (MAR); 50 imputed 
datasets will be generated. If MI is considered necessary, aggregated analyses of the imputed 
datasets will be calculated. However, assuming data missing not at random (MNAR) we will 
conduct analyses as best-worse and worse-best scenarios where data from missing response 
from survivors will be imputed using the mean +/- 1 standard deviation of the EQ-5D-5L and Mini 










This article is protected by copyright. All rights reserved
Discussion
With this long-term follow-up study, we aim to establish how restrictive vs standard-care IV fluid 
therapy affects long-term patient-important outcomes in adult patients with septic shock. The 
strength of our study includes being based on a large international RCT, which aims to provide us 
with high-quality evidence and with lowest possible risk of bias. The protocol for the CLASSIC 
trial, including the long-term follow-up after 1 year, and statistical analysis plan (SAP) was 
defined and published prior to the end of the trial.10 
The limitations of our long-term follow-up include lack of a baseline EQ-5D-5L or MoCA score, 
which can lead to a potential baseline imbalance in HRQoL and cognitive function, which may be 
present but un-detected. The Mini MoCA is not validated for critically ill patients and it only 
detects mild cognitive impairment. Patients surviving sepsis may have long-term moderate to 
severe cognitive impairment.4 Therefore, cognitive impairment could potentially be 
underestimated with the Mini MoCA score. We will evaluate the use of the Mini MoCA tool, 
which to our knowledge has not previously been used in a RCT as long-term outcome in critically 
ill patients. Furthermore, evaluation of a simple and short tool measuring an important patient 
outcome will add significant value for future research. 
Conclusion
We will assess HRQoL and cognitive function one year after patients with septic shock have been 
included in the CLASSIC trial. This will provide us with essential knowledge of long-term benefits 
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